Studies on interactions between plasminogen activator-containing fluids and avain and murine lymphocytes.
D000818:Animals; D001358:Avian Sarcoma Viruses / Q000276:immunology; D002471:Cell Transformation, Neoplastic; D002478:Cells, Cultured; D002645:Chickens; D005260:Female; D005342:Fibrinolysis; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008934:Mitogens / Q000037:antagonists & inhibitors / Q000494:pharmacology; D010447:Peptide Hydrolases / Q000494:pharmacology; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology; D015849:Plasminogen Inactivators; D012513:Sarcoma, Experimental / Q000276:immunology; D014568:Urokinase-Type Plasminogen Activator / Q000494:pharmacology
D008934:Mitogens; D015849:Plasminogen Inactivators; D010447:Peptide Hydrolases; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator